Nova Southeastern University Office of Academic Affairs Search NSU Site Map Nova Southeastern University
President's Faculty R & D Grant 
Home
Committees, Councils
  and Boards
Faculty Policy Manual
NSU Scholarly Journals
Professional Journals
Prof. Memberships
Policies & Procedures
Provost's Research and Scholarship Award
President's Faculty
 R & D Grant
PFRDG Application Review Process by NSU Librarians
Faculty Resources
Student Resources
Contact Us

Print this page  

 


With a focus on learning, we employ a range of strategies to support innovation, collaboration across centers, and university-wide discussion and decision-making

 

Fourteenth Annual Grant Winners 2013-2014

Title

Formulation and Diffusion of Epinephrine's Prodrug for Anaphylaxis Treatment

Dean

Andres Malave, Ph.D. (HPD-PHR)
Lisa Deziel-Evans, Pharm.D., Ph.D. (HPD-PHR)

Faculty and Students

Mutasem Rawas-Qalaji, Ph.D. (HPD-PHR)
Arghavan Kariman, B.S. (HPD-PHR)
Michael Condon, B.S. (HPD-PHR)
Annette Losada (HPD-PHR)                 
Belacryst Mandez, B.S. (HPD-PHR)
Alhussain Aodah, B.Pharm. (HPD-PHR)

Abstract

Rawas-Qalaji, Kariman, Condon, Losada, Mandez, AodahAnaphylaxis may follow the exposure of susceptible persons to an antigen such as food and medication. Prompt intramuscular injection of epinephrine in the thigh is the treatment of choice. Most anaphylactic reactions occur unexpectedly and the failure to administer epinephrine promptly may result in the death of patients. Epinephrine for self-administration, e.g. EpiPen autoinjectors, is available but underutilized. Therefore, alternative methods of administering epinephrine are being explored. Previously, we were able to develop and evaluate rapidly-disintegrating sublingual epinephrine tablets. Our studies showed that sublingually administered epinephrine is absorbed in both animals and humans, however, the relative bioavailability is very low, 0.6%. Dipivefrin is an epinephrine prodrug that is approved for the treatment of glaucoma as an eye drop (Propine, 0.1%).Dipivefrin has better biopharmaceutical properties than epinephrine and hence better bioavailability. Our objectives are to formulate dipivefrin into rapidly-disintegrating sublingual tablets and test their diffusion in vitro and ex vivo using dialysis and excised sublingual mucosal membranes, respectively. Dipivefrin sublingual tablets will be formulated using our previously patented formulation. Tablets will be evaluated for weight variation, content uniformity, friability, dimension, hardness, and disintegration time using the harmonized USP methods and criteria. The diffusion of 10, 20, and 40 mg dipivefrin (n=6) will be evaluated using a Franz Cells Diffusion System. Dipivefrin 10 mg solution and 40 mg epinephrine tablets will be used as controls. The mean±SDcumulative diffused dipivefrin and percentage, influx (J), permeability, and lag time will be calculated. The area under the curve (JAUC0-90), the maximum diffusion (Jmax), and the time to reach Jmax (Tmax) will be calculated and statistically compared by one-way ANOVA. Studies will be designed with a power of ≥80 and α<0.05.Dipivefrin sublingual tablets will offer efficient, non-invasive, and patient-friendly delivery system with fewer side effects than epinephrine injection for the treatment of anaphylaxis.